RxSight, Inc. to Report Second Quarter 2025 Financial Results on August 7, 2025

Rhea-AI Summary

RxSight (NASDAQ:RXST), an ophthalmic medical device company focused on customized vision solutions for post-cataract surgery patients, has scheduled its Q2 2025 financial results announcement for August 7, 2025, after market close.

The company will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Investors can join via phone using the numbers (800) 715-9871 or (646) 307-1963 with conference code 633359, or listen to the webcast through the company's investor relations website.

News Market Reaction – RXST

+0.38%

+0.38% Session move

In the trading session that priced this news, RXST gained 0.38%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ALISO VIEJO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the second quarter of 2025 after the market close on Thursday, August 7, 2025. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 633359. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com

Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com

FAQ

When will RxSight (RXST) report Q2 2025 earnings?

RxSight will report its Q2 2025 financial results on Thursday, August 7, 2025, after the market close.

What time is RxSight's Q2 2025 earnings call?

RxSight's Q2 2025 earnings conference call will begin at 1:30 PM Pacific Time / 4:30 PM Eastern Time on August 7, 2025.

How can I listen to RxSight's Q2 2025 earnings call?

You can join by dialing (800) 715-9871 or (646) 307-1963 with conference code 633359, or listen to the webcast at investors.rxsight.com.

What does RxSight (RXST) company do?

RxSight is an ophthalmic medical device company that provides high-quality customized vision solutions to patients following cataract surgery.